The U.S. has approved a groundbreaking twice-a-year shot, lenacapvir, for HIV prevention, potentially transforming care. Experts suggest this could significantly reduce new infections.
A groundbreaking study reveals that combining Trodelvy and Keytruda reduces tumor progression risk by over a third in aggressive breast cancer cases, paving the way for new treatment options.
